AACR 2025: A liquid biopsy-based assay could detect recurrence prior to imaging in patients with resectable colorectal cancer
An ultrasensitive circulating tumour DNA (ctDNA)-based liquid biopsy assay detected signs of recurrence before imaging…
An ultrasensitive circulating tumour DNA (ctDNA)-based liquid biopsy assay detected signs of recurrence before imaging…
An artificial intelligence (AI)-based model accurately classified paediatric sarcomas using digital pathology images alone, according…
About 90% of deaths from cancer are a result of metastasis — that is, from…
Certain proteogenomic signatures in the prostate cancers of men of African and European ancestries were…
TG4050, a personalised neoantigen vaccine, induced tumour-specific immune responses and led to low rates of…
A blood-based machine learning assay that combines cell-free DNA (cfDNA) fragment patterns and levels of…
AZD1390, an ataxia telangiectasia mutant (ATM) kinase inhibitor, demonstrated a manageable safety profile in both…
An investigational exosome-based liquid biopsy accurately detected 97% of stage 1-2 pancreatic cancers when combined…
The Phase 1/2 LINKER-MM1 trial of linvoseltamab in patients with relapsed/refractory (R/R) multiple myeloma (MM)…
In a study presented today at the American Association for Cancer Research (AACR) Annual Meeting…